关键词: Lacrimal functional unit Primary acquired nasolacrimal duct obstruction Schirmer Tear break-up time Tear film instability Tear osmolarity

Mesh : Humans Lacrimal Duct Obstruction / diagnosis Nasolacrimal Duct Prospective Studies Tears Osmolar Concentration Dry Eye Syndromes

来  源:   DOI:10.1007/s10792-022-02498-w

Abstract:
OBJECTIVE: To measure tear osmolarity, Schirmer I test and tear break-up time (TBUT) values in the obstructed and non-obstructed fellow eye of unilateral primary acquired nasolacrimal duct obstruction (PANDO) patients and compare them with healthy controls.
METHODS: In this prospective noninterventional study, the tear osmolarity, Schirmer I test, and TBUT values from unilateral PANDO eyes, fellow eyes, and control eyes of all subjects were measured.
RESULTS: The study included 114 eyes of 30 PANDO patients as well as 27 healthy controls. There was a significant difference between TBUT and Schirmer values of fellow eyes and PANDO eyes (p = 0,035; p = 0,001). There was no significant difference in any of the ocular surface parameters between PANDO eyes and control eyes (p > 0.05). When fellow eyes were compared to control eyes, there was a significant difference in TBUT (p = 0.046).
CONCLUSIONS: Decreased TBUT was exhibited by the fellow eye of unilateral PANDO patients, compared to the PANDO side and controls. Compensatory changes in PANDO eyes due to a decrease in the tear secretion reflex may lead to tear dysfunction of the fellow eye. Clinicians should assess tear stability in the fellow eye of PANDO patients as this could be leading to added symptomatic complaints.
摘要:
目的:测量泪液渗透压,单侧原发性获得性鼻泪管阻塞(PANDO)患者的阻塞和非阻塞眼的SchirmerI测试和泪液破裂时间(TBUT)值,并将其与健康对照进行比较。
方法:在这项前瞻性非干预研究中,眼泪渗透压,Schirmer我测试,和单侧PANDO眼睛的TBUT值,同伴的眼睛,测量所有受试者的对照眼。
结果:该研究包括30名PANDO患者的114只眼以及27名健康对照。同伴眼和PANDO眼的TBUT和Schirmer值之间存在显着差异(p=0.035;p=0.001)。PANDO眼和对照眼之间的任何眼表参数都没有显着差异(p>0.05)。当同伴眼睛与对照眼睛相比时,TBUT差异有统计学意义(p=0.046)。
结论:单侧PANDO患者的眼睛表现出TBUT减少,与PANDO侧和控制相比。由于泪液分泌反射的减少而引起的PANDO眼睛的代偿性变化可能导致对侧眼睛的泪液功能障碍。临床医生应评估PANDO患者的双眼泪液稳定性,因为这可能会导致更多的症状投诉。
公众号